{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:42Z","timestamp":1790882382091,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.mib.2006.08.001","type":"journal-article","created":{"date-parts":[[2006,8,10]],"date-time":"2006-08-10T11:53:52Z","timestamp":1155210832000},"page":"483-488","source":"Crossref","is-referenced-by-count":52,"title":["Clinical efficacy of new antifungal agents"],"prefix":"10.1016","volume":"9","author":[{"given":"Carol A","family":"Kauffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2006.08.001_bib1","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2006.08.001_bib2","unstructured":"Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, Walsh T: Abstract M-718: Anidulafungin vs fluconazole for treatment of candidemia and invasive candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16\u201319, 2005."},{"key":"10.1016\/j.mib.2006.08.001_bib3","unstructured":"Ruhnke M, Kuse ER, Chetchotisakd P, Arns Da Cunha C, Diekmann-Berndt H: Abstract M-722c: Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16\u201319, 2005."},{"key":"10.1016\/j.mib.2006.08.001_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.49.2.767-769.2005","article-title":"Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis","volume":"49","author":"Moudgal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/AAC.48.4.1382-1383.2004","article-title":"Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis","volume":"48","author":"Hernandez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1086\/500939","article-title":"Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient","volume":"42","author":"Krogh-Madsen","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib8_1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/501020","article-title":"Micafungin: a new echinocandin","volume":"42","author":"Chandrasekar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.mib.2006.08.001_bib10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2006.08.001_bib11","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib12","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib14","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib16_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconzole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2006.08.001_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1086\/428734","article-title":"Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases","volume":"40","author":"Mouas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.mib.2006.08.001_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1086\/421950","article-title":"Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases","volume":"39","author":"Steinbach","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib21","unstructured":"Raad II, Chapman S, Bradsher R, Morrison V, Goldman M, Graybill J, Perfect JR, Patterson T, Walsh T, Corcoran G, Pappas P: Abstract M-669: Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30\u2013November 2, 2004."},{"key":"10.1016\/j.mib.2006.08.001_bib22","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib23_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/426445","article-title":"Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome","volume":"40","author":"Husain","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib24_1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib25","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1086\/429331","article-title":"Treatment of non-Aspergillus moulds in immunocompromised patients with amphotericin B lipid complex","volume":"40","author":"Perfect","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/383319","article-title":"Fusarium infection in hematopoietic stem cell transplant recipients","volume":"38","author":"Nucci","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422729","article-title":"Zygomycosis: reemergence of an old pathogen","volume":"39","author":"Kauffman","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib28_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib30_1","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"Van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib31_1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib32_1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2006.08.001_bib33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1086\/501457","article-title":"A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV\/AIDS","volume":"42","author":"Vazquez","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1467-8365.2005.00105.x","article-title":"Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center","volume":"7","author":"Freifeld","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib35","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/429319","article-title":"Successful treatment of cerebral blastomycosis with voriconazole","volume":"40","author":"Bakleh","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib36","first-page":"39","article-title":"Successful management of Blastomyces dermatitidis meningitis","volume":"23","author":"Lentnek","year":"2006","journal-title":"Infect Med"},{"key":"10.1016\/j.mib.2006.08.001_bib37","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1086\/375235","article-title":"Sucessful treatment of coccidioidal meningitis with voriconazole","volume":"36","author":"Cortez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib38","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/AAC.48.6.2341.2004","article-title":"Successful use of voriconazole for treatment of Coccidioides meningitis","volume":"48","author":"Proia","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib39","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1086\/424019","article-title":"Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole","volume":"39","author":"Prabhu","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib40","article-title":"Salvage treatment of histoplasmosis with posaconazole","author":"Restrepo","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.mib.2006.08.001_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","article-title":"Activity of posaconazole in the treatment of central nervous system fungal infections","volume":"56","author":"Pitisuttithum","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib42","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jinf.2005.01.001","article-title":"A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole","volume":"51","author":"Clark","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.mib.2006.08.001_bib43_1","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1086\/430303","article-title":"Refractory coccidioidomycosis treated with posaconazole","volume":"40","author":"Anstead","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2006.08.001_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2006.08.001_bib45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2006.08.001_bib46","unstructured":"Cornely OA, Maertens J, Winston DJ et al.: Abstract M-722b: Posaconazole vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome: impact on mortality. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16\u201319, 2005"},{"key":"10.1016\/j.mib.2006.08.001_bib47","unstructured":"Ullmann AJ, Lipton JH, Vesole DH et al.: Abstract M-716: Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16\u201319, 2005."}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527406001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527406001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T10:56:38Z","timestamp":1547463398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527406001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S1369527406001238"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2006.08.001","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}